Open Access
Review
Integrins as Drug Targets in Vascular and Related Diseases
Emily Meredith1, *
, Martin A. Schwartz1, 2, 3
Author Information
Submitted: 6 Apr 2024 | Revised: 28 May 2024 | Accepted: 29 May 2024 | Published: 21 Jun 2024
Abstract
Integrins are transmembrane receptors that, as critical participants in a vast range of pathological processes, are potential therapeutic targets. However, in only a few cases has the promise been realized by drug approval. In this review, we briefly review basic integrin biology and participation in disease, challenges in the development of safe, effective integrin-targeted therapies, and recent advances that may lead to progress.
Keywords
References
1.
Takada, Y.; Ye, X.; Simon, S. The integrins. Genome Biol. 2007, 8, 215.
2.
Hynes, R.O. The emergence of integrins: A personal and historical perspective. Matrix Biol. 2004, 23, 333–340, https://doi.org/10.1016/j.matbio.2004.08.001.
3.
Morse, E.M.; Brahme, N.N.; Calderwood, D.A. Integrin Cytoplasmic Tail Interactions. Biochemistry 2014, 53, 810–820, https://doi.org/10.1021/bi401596q.
4.
Laeremans, T.; Sands, Z.A.; Claes, P.; et al. Accelerating GPCR drug discovery with conformation-stabilizing VHHs. Front. Mol. Biosci. 2022, 9, 863099, https://doi.org/10.3389/fmolb.2022.863099.
5.
Zhang, H.; Zhu, D.S.; Zhu, J. Family-wide analysis of integrin structures predicted by αFold2. Comput. Struct. Biotechnol. J. 2023, 21, 4497–4507, https://doi.org/10.1016/j.csbj.2023.09.022.
6.
Trimm, E.; Red-Horse, K. Vascular endothelial cell development and diversity. Nat. Rev. Cardiol. 2022, 20, 197–210, https://doi.org/10.1038/s41569-022-00770-1.
7.
Baeyens, N.; Bandyopadhyay, C.; Coon, B.G.; et al. Endothelial fluid shear stress sensing in vascular health and disease. J. Clin. Investig. 2016, 126, 821–828, doi:10.1172/jci83083.
8.
Li, F.; Yan, K.; Wu, L.; et al. Single-cell RNA-seq reveals cellular heterogeneity of mouse carotid artery under disturbed flow. Cell. Death Discov. 2021, 7, 1–14, https://doi.org/10.1038/s41420-021-00567-0.
9.
Tzima, E.; del Pozo, M.A.; Shattil, S.J.; et al. Activation of integrins in endothelial cells by fluid shear stress mediates Rho-dependent cytoskeletal alignment. EMBO J. 2001, 20, 4639–4647, https://doi.org/10.1093/emboj/20.17.4639.
10.
Finney, A.C.; Stokes, K.Y.; Pattillo, C.B.; et al. Integrin signaling in atherosclerosis. Cell. Mol. Life Sci. 2017, 74, 2263–2282, https://doi.org/10.1007/s00018-017-2490-4.
11.
Chen, P.Y.; Qin, L.; Baeyens, N.; et al. Endothelial-to-mesenchymal transition drives atherosclerosis progression. J. Clin. Invest. 2015, 125, 4514–4528.
12.
Yun, S.; Budatha, M.; Dahlman, J.E.; et al. Interaction between integrin α5 and PDE4D regulates endothelial inflammatory signalling. Nature 2016, 18, 1043–1053, https://doi.org/10.1038/ncb3405.
13.
Yun, S.; Hu, R.; Schwaemmle, M.E.; et al. Integrin α5β1 regulates PP2A complex assembly through PDE4D in atherosclerosis. J. Clin. Invest. 2019, 129, 4863–4874.
14.
Piera-Velazquez, S.; Jimenez, S.A. Endothelial to mesenchymal transition: Role in physiology and in the pathogenesis of human diseases. Physiol. Rev. 2019, 99, 1281–1324, https://doi.org/10.1152/physrev.00021.2018.
15.
Allahverdian, S.; Chaabane, C.; Boukais, K.; et al. Smooth muscle cell fate and plasticity in atherosclerosis. Cardiovasc. Res. 2018, 114, 540–550, doi:10.1093/cvr/cvy022.
16.
Misra, A.; Feng, Z.; Chandran, R.R.; et al. Integrin beta3 regulates clonality and fate of smooth muscle-derived atherosclerotic plaque cells. Nat. Commun. 2018, 9, 2073, https://doi.org/10.1038/s41467-018-04447-7.
17.
Zhang, Y.; Wang, H. Integrin signalling and function in immune cells. Immunology 2012, 135, 268–275, https://doi.org/10.1111/j.1365-2567.2011.03549.x.
18.
Renshall, L.; Arnold, N.; West, L.; et al. Selective improvement of pulmonary arterial hypertension with a dual ET(A)/ET(B) receptors antagonist in the apolipoprotein E-/- model of PAH and atherosclerosis. Pulm. Circ. 2018, 8, 2045893217752328.
19.
Reed, D.; Reed, C.; Stemmermann, G.; et al. Are aortic aneurysms caused by atherosclerosis? Circulation 1992, 85, 205–211.
20.
Nickel, N.P.; Yuan, K.; Dorfmuller, P.; et al., Beyond the lungs: Systemic manifestations of pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2020, 201, 148–157.
21.
Maleki, S.; Poujade, F.-A.; Bergman, O.; et al. Endothelial/epithelial mesenchymal transition in ascending aortas of patients with bicuspid aortic valve. Front. Cardiovasc. Med. 2019, 6, 182, https://doi.org/10.3389/fcvm.2019.00182.
22.
Jia, D.; Zhu, Q.; Liu, H.; et al. Osteoprotegerin disruption attenuates hysu-induced pulmonary hypertension through integrin αvβ3/FAK/AKT pathway suppression. Circ. Cardiovasc Genet. 2017, 10, e001591.
23.
Blanchard, N.; Link, P.A.; Farkas, D.; et al., Dichotomous role of integrin-β5 in lung endothelial cells. Pulm. Circ. 2022, 12, e12156.
24.
Andre, P.; Joshi, S.R.; Briscoe, S.D.; et al. Therapeutic approaches for treating pulmonary arterial hypertension by correcting imbalanced TGF-β superfamily signaling. Front. Med. 2021, 8, 814222.
25.
Shochet, G.E.; Brook, E.; Bardenstein-Wald, B.; et al. Integrin α-5 silencing leads to myofibroblastic differentiation in IPF-derived human lung fibroblasts. Ther. Adv. Chronic Dis. 2020, 11, 2040622320936023, https://doi.org/10.1177/2040622320936023.
26.
Chen, H.; Qu, J.; Huang, X.; et al. Mechanosensing by the α6-integrin confers an invasive fibroblast phenotype and mediates lung fibrosis. Nat. Commun. 2016, 7, 12564, https://doi.org/10.1038/ncomms12564.
27.
Manso, A.M.; Kang, S.M.; Ross, R.S. Integrins, focal adhesions, and cardiac fibroblasts. J. Investig. Med. 2009, 57, 856–60.
28.
Guo, D.C.; Papke, C.L.; He, R.; et al. Pathogenesis of thoracic and abdominal aortic aneurysms. Ann. N.Y. Acad. Sci. 2006, 1085, 339–352.
29.
Chen, M.; Cavinato, C.; Hansen, J.; et al. FN (Fibronectin)-Integrin α5 signaling promotes thoracic aortic aneurysm in a mouse model of marfan syndrome. Arter. Thromb. Vasc. Biol. 2023, 43, E132–E150, https://doi.org/10.1161/atvbaha.123.319120.
30.
Nakamura, K.; Dalal, A.R.; Yokoyama, N.; et al. Lineage-Specific induced pluripotent stem cell–derived smooth muscle cell modeling predicts integrin alpha-v antagonism reduces aortic root aneurysm formation in marfan syndrome mice. Arter. Thromb. Vasc. Biol. 2023, 43, 1134–1153, https://doi.org/10.1161/atvbaha.122.318448.
31.
Pan, L.; Bai, P.; Weng, X.; et al., Legumain is an endogenous modulator of integrin αvβ3 triggering vascular degeneration, dissection, and rupture. Circulation 2022, 145, 659–674.
32.
Wu, P.H.; Opadele, A.E.; Onodera, Y.; et al., Targeting integrins in cancer nanomedicine: Applications in cancer diagnosis and therapy. Cancers 2019, 11, 1783.
33.
Hamidi, H.; Ivaska, J. Every step of the way: Integrins in cancer progression and metastasis. Nat. Rev. Cancer 2018, 18, 533–548, https://doi.org/10.1038/s41568-018-0038-z.
34.
Sloan, E.K.; Pouliot, N.; Stanley, K.L.; et al., Tumor-specific expression of αvβ3 integrin promotes spontaneous metastasis of breast cancer to bone. Breast Cancer Res. 2006, 8, 1–14.
35.
Bergonzini, C.; Kroese, K.; Zweemer, A.J.M.; et al. Targeting integrins for cancer therapy - disappointments and opportunities. Front. Cell. Dev. Biol. 2022, 10, 863850, https://doi.org/10.3389/fcell.2022.863850.
36.
Janus-Bell, E.; Mangin, P.H. The relative importance of platelet integrins in hemostasis, thrombosis and beyond. Haematologica 2023, 108, 1734–1747, https://doi.org/10.3324/haematol.2022.282136.
37.
Stark, K.; Massberg, S. Interplay between inflammation and thrombosis in cardiovascular pathology. Nat. Rev. Cardiol. 2021, 18, 666–682, https://doi.org/10.1038/s41569-021-00552-1.
38.
Estevez, B.; Shen, B.; Du, X.; et al. Targeting integrin and integrin signaling in treating thrombosis. Arter. Thromb. Vasc. Biol. 2015, 35, 24–29, https://doi.org/10.1161/atvbaha.114.303411.
39.
Goligorsky, M.S. Microvascular rarefaction: The decline and fall of blood vessels. Organogenesis 2010, 6, 1–10.
40.
Honce, J.M.; Nagae, L.; Nyberg, E. Neuroimaging of natalizumab complications in multiple sclerosis: PML and other associated entities. Mult. Scler. Int. 2015, 2015, 1–14, https://doi.org/10.1155/2015/809252.
41.
Kawamoto, E.; Nakahashi, S.; Okamoto, T.; et al. Anti-integrin therapy for multiple sclerosis. Autoimmune Dis. 2012, 2012, 1–6, https://doi.org/10.1155/2012/357101.
42.
Cohen, S.A.; Trikha, M.; Mascelli, M.A. Potential future clinical applications for the GPIIb/IIIa antagonist, abciximab in thrombosis, vascular and oncological indications. Pathol. Oncol. Res. 2000, 6, 163–174, https://doi.org/10.1007/bf03032368.
43.
Nishimura, S.L. Integrin-mediated transforming growth factor-beta activation, a potential therapeutic target in fibrogenic disorders. Am. J. Pathol. 2009, 175, 1362–1370.
44.
Miller, P.B.; Parnell, B.A.; Bushnell, G.; et al. Endometrial receptivity defects during IVF cycles with and without letrozole. Hum. Reprod. 2012, 27, 881–888.
45.
Chen, Y.F.; Yang, Y.N.; Chu, H.R.; et al. Role of Integrin alphavbeta3 in Doxycycline-Induced Anti-Proliferation in Breast Cancer Cells. Front. Cell Dev. Biol. 2022, 10, 829788.
46.
Kondo, K.; Umemura, K. Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: Comparison with the monoclonal antibody abciximab. Clin. Pharmacokinet. 2002, 41, 187–195.
47.
Tonin, G.; Klen, J. Eptifibatide, an older therapeutic peptide with new indications: From clinical pharmacology to everyday clinical practice. Int. J. Mol. Sci. 2023, 24, 5446, https://doi.org/10.3390/ijms24065446.
48.
Stuve, O.; Bennett, J.L. Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases. CNS Drug Rev. 2007, 13, 79–95.
49.
Zaheer, F.; Berger, J.R. Treatment-related progressive multifocal leukoencephalopathy: Current understanding and future steps. Ther. Adv. Drug Saf. 2012, 3, 227–239, https://doi.org/10.1177/2042098612453849.
50.
Monschein, T.; Dekany, S.; Zrzavy, T.; et al. Real-world use of natalizumab in Austria: Data from the Austrian Multiple Sclerosis Treatment Registry (AMSTR). J. Neurol. 2023, 270, 3779–3786.
51.
Moser, T.; Zimmermann, G.; Baumgartner, A.; et al., Long-term outcome of natalizumab-associated progressive multifocal leukoencephalopathy in Austria: A nationwide retrospective study. J. Neurol. 2024, 271, 374–385.
52.
Kim, J.; Kim, C.; Lee, J.A.; et al. Long-term prognosis and overall mortality in patients with progressive multifocal leukoencephalopathy. Sci. Rep. 2023, 13, 14291.
53.
Anton, R.; Haas, M.; Arlett, P.; et al. Drug-induced progressive multifocal leukoencephalopathy in multiple sclerosis: European regulators’ perspective. Clin. Pharmacol. Ther. 2017, 102, 283–289.
54.
McClellan, K.J.; Goa, K.L. Tirofiban. A review of its use in acute coronary syndromes. Drugs 1998, 56, 1067–1080.
55.
Zhou, X.; Wu, X.; Sun, H.; et al. Efficacy and safety of eptifibatide versus tirofiban in acute coronary syndrome patients: A systematic review and meta-analysis. J. Evid. Based Med. 2017, 10, 136–144.
56.
Puri, A.; Bansal, A.; Narain, V.; et al. Comparative assessment of platelet GpIIb/IIIa receptor occupancy ratio with Eptifibatide/Tirofiban in patients presenting with ACS and undergoing PCI. Indian Hear. J. 2012, 65, 152–157, https://doi.org/10.1016/j.ihj.2012.08.007.
57.
Movva, H.; Rabah, R.; Tekle, W.; et al. There is no difference in safety and efficacy with Tirofiban or Eptifibatide for patients undergoing treatment of large vessel occlusion and underlying intracranial atherosclerosis. Interdiscip. Neurosurg. 2020, 23, 100927, https://doi.org/10.1016/j.inat.2020.100927.
58.
Lin, F.Y.; Li, J.; Xie, Y.; et al., A general chemical principle for creating closure-stabilizing integrin inhibitors. Cell. 2022, 185, 3533–3550.
59.
Zhu, J.; Zhu, J.; Springer, T.A. Complete integrin headpiece opening in eight steps. J. Cell. Biol. 2013. 201, 1053–1068.
60.
Abrams, C.S.; Cines, D.B. Thrombocytopenia after treatment with platelet glycoprotein IIb/IIIa inhibitors. Curr. Hemat. Rep. 2004, 3, 143–147.
61.
Blue, R.; Murcia, M.; Karan, C.; et al. Application of high-throughput screening to identify a novel αIIb-specific small- molecule inhibitor of αIIbβ3-mediated platelet interaction with fibrinogen. Blood 2008, 111, 1248–1256.
62.
Zhu, J.; Choi, W.S.; McCoy, J.G.; et al. Structure-guided design of a high-affinity platelet integrin αIIbβ3 receptor antagonist that disrupts Mg2+ binding to the MIDAS. Sci. Transl. Med. 2012, 4, 125ra32.
63.
Hülskamp, M.D.; Kronenberg, D.; Stange, R. The small-molecule protein ligand interface stabiliser E7820 induces differential cell line specific responses of integrin α2 expression. BMC Cancer 2021, 21, 1–12, https://doi.org/10.1186/s12885-021-08301-w.
64.
Funahashi, Y.; Sugi, N.H.; Semba, T.; et al. Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin α2 subunit on endothelium. Cancer Res. 2002, 62, 6116–6123.
65.
Mita, M.; Kelly, K.R.; Mita, A.; et al. Phase I study of E7820, an oral inhibitor of integrin α-2 expression with antiangiogenic properties, in patients with advanced malignancies. Clin. Cancer Res. 2011, 17, 193–200.
66.
McCarty, J.H. αvβ8 integrin adhesion and signaling pathways in development, physiology and disease. J. Cell. Sci. 2020, 133, jcs239434.
67.
Ansari, M.J.; Bokov, D.; Markov, A.; et al. Cancer combination therapies by angiogenesis inhibitors; a comprehensive review. Cell. Commun. Signal. 2022, 20, 1–23, https://doi.org/10.1186/s12964-022-00838-y.
68.
Lokugamage, N.; Chowdhury, I.H.; Biediger, R.J.; et al. Use of a small molecule integrin activator as a systemically administered vaccine adjuvant in controlling Chagas disease. npj Vaccines 2021, 6, 1–14, https://doi.org/10.1038/s41541-021-00378-5.
69.
Bondarev, A.D.; Attwood, M.M.; Jonsson, J.; et al. Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules. Front. Pharmacol. 2022, 13, 1057083.
70.
Shen, B.; Zhao, X.; O’brien, K.A.; et al. A directional switch of integrin signalling and a new anti-thrombotic strategy. Nature 2013, 503, 131–135, https://doi.org/10.1038/nature12613.
71.
Kapp, T.G.; Rechenmacher, F.; Neubauer, S.; et al. A comprehensive evaluation of the activity and selectivity profile of ligands for rgd-binding integrins. Sci. Rep. 2017, 7, 39805.
72.
Slack, R.J.; Macdonald, S.J.F.; Roper, J.A.; et al. Emerging therapeutic opportunities for integrin inhibitors. Nat. Rev. Drug Discov. 2021, 21, 60–78, https://doi.org/10.1038/s41573-021-00284-4.
73.
Hersey, P.; Sosman, J.; O’Day, S.; et al. A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin αvβ3, + or - dacarbazine in patients with stage IV metastatic melanoma. Cancer 2010, 116, 1526–1534.
74.
Park, C.H.; Yoo, T.H. TGF-beta inhibitors for therapeutic management of kidney fibrosis. Pharmaceuticals 2022, 15, 1485.
75.
Sant, S.; Johnston, P.A. The production of 3D tumor spheroids for cancer drug discovery. Drug Discov. Today: Technol. 2017, 23, 27–36, https://doi.org/10.1016/j.ddtec.2017.03.002.
76.
Ramadan, Q.; Sharma, P. Editorial: Tissue engineering for drug discovery and personalized medicine. Front. Med. Technol. 2021, 3, 663057, https://doi.org/10.3389/fmedt.2021.663057.
77.
Jain, P.; Kathuria, H.; Dubey, N. Advances in 3D bioprinting of tissues/organs for regenerative medicine and in-vitro models. Biomaterials 2022, 287, 121639, https://doi.org/10.1016/j.biomaterials.2022.121639.
78.
Usman Khan, M.; Cai, X.; Shen, Z.; et al. Challenges in the development and application of organ-on-chips for intranasal drug delivery studies. Pharmaceutics 2023, 15, 1557.
79.
Phan, T.H.; Shi, H.; Denes, C.E.; et al. Advanced pathophysiology mimicking lung models for accelerated drug discovery. Biomater. Res. 2023, 27, 35.
80.
Zou, W.; Teitelbaum, S.L. Absence of Dap12 and the αvβ3 integrin causes severe osteopetrosis. J. Cell. Biol. 2015, 208, 1251–36.
81.
West, C.; Tobo, C.; Au, J.; et al. Combined application of biosponges and an antifibrotic agent for the treatment of volumetric muscle loss. Am. J. Physiol. Physiol. 2023, 324, C1341–C1352, https://doi.org/10.1152/ajpcell.00092.2023.
82.
Dahlman, J.E.; Barnes, C.; Khan, O.F.; et al. In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight. Nat. Nanotechnol. 2014, 9, 648–655, https://doi.org/10.1038/nnano.2014.84.
83.
Cappelluti, M.A.; Poeta, V.M.; Valsoni, S.; et al. Durable and efficient gene silencing in vivo by hit-and-run epigenome editing. Nature 2024, 627, 416–423, https://doi.org/10.1038/s41586-024-07087-8.
84.
Lenz, T.; Koch, T.; Joner, M.; et al. Ten‐Year clinical outcomes of biodegradable versus durable polymer new‐generation drug‐eluting stent in patients with coronary artery disease with and without diabetes mellitus. J. Am. Hear. Assoc. 2021, 10, e020165, https://doi.org/10.1161/jaha.120.020165.
85.
Pandey, N. AXT107 an inhibitor of neovascularization, vascular leakage, and inflammation, is well-tolerated and could potentially be dosed once a year to treat retinal vascular diseases. Invest. Ophthalmology Visual Sci. 2021, 62, 3304–3304.
86.
Joshi, A. Microparticulates for ophthalmic drug delivery. J. Ocul. Pharmacol. Ther. 1994, 10, 29–45, https://doi.org/10.1089/jop.1994.10.29.
87.
Kim, H.S.; Kang, J.; Hwang, D.; et al. Durable polymer versus biodegradable polymer drug-eluting stents after percutaneous coronary intervention in patients with acute coronary syndrome: The HOST-REDUCE-POLYTECH-ACS trial. Circulation 2021, 143, 1081–1091.
88.
Yamaji, K.; Kimura, T.; Morimoto, T.; et al. Very long-term (15 to 20 years) clinical and angiographic outcome after coronary bare metal stent implantation. Circ. Cardiovasc. Interv. 2010, 3, 468–475.
89.
Blindt, R.; Vogt, F.; Astafieva, I.; et al. A novel drug-eluting stent coated with an integrin-binding cyclic arg-gly-asp peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cells. J. Am. Coll. Cardiol. 2006, 47, 1786–1795, https://doi.org/10.1016/j.jacc.2005.11.081.
90.
Wang, W.; Wang, Z.; Tian, D.; et al. Integrin β3 mediates the endothelial-to-mesenchymal transition via the notch pathway. Cell. Physiol. Biochem. 2018, 49, 985.
91.
Evrard, S.M.; Lecce, L.; Michelis, K.C.; et al. Endothelial to mesenchymal transition is common in atherosclerotic lesions and is associated with plaque instability. Nat. Commun. 2016, 7, 11853, https://doi.org/10.1038/ncomms11853.
92.
Kabir, I.; Zhang, X.; Dave, J.M.; et al. The age of bone marrow dictates the clonality of smooth muscle-derived cells in atherosclerotic plaques. Nat. Aging 2023, 3, 64–81, https://doi.org/10.1038/s43587-022-00342-5.
93.
Bricelj, A.; Steinebach, C.; Kuchta, R.; et al. E3 ligase ligands in successful PROTACs: An overview of syntheses and linker attachment points. Front. Chem. 2021, 9, 707317, https://doi.org/10.3389/fchem.2021.707317.
94.
Layman, R.M.; Jerzak, K.J.; Hilton, J.F.; et al. TACTIVE-U: Phase 1b/2 umbrella study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, combined with other anticancer treatments in ER+ advanced or metastatic breast cancer. J. Clin. Oncol. 2023, 41, TPS1121–TPS1121, https://doi.org/10.1200/jco.2023.41.16_suppl.tps1121.
95.
Hynes, R.O. A reevaluation of integrins as regulators of angiogenesis. Nat. Med. 2002, 8, 918–921, https://doi.org/10.1038/nm0902-918.
96.
Demircioglu, F.; Hodivala-Dilke, K. αvβ3 Integrin and tumour blood vessels-learning from the past to shape the future. Curr. Opin. Cell. Biol. 2016, 42, 121–127.
97.
Mahabeleshwar, G.H.; Feng, W.; Phillips, D.R.; et al. Integrin signaling is critical for pathological angiogenesis. J. Exp. Med. 2006, 203, 2495–2507, https://doi.org/10.1084/jem.20060807.
98.
Liao, Z.; Kato, H.; Pandey, M.; et al. Interaction of kindlin-2 with integrin β3 promotes outside-in signaling responses by the αVβ3 vitronectin receptor. Blood 2015, 125, 1995–2004.
Issue
Volume 3, Issue 2How to Cite
Meredith, E., & A. Schwartz, M. (2024). Integrins as Drug Targets in Vascular and Related Diseases. International Journal of Drug Discovery and Pharmacology, 3(2), 100010. https://doi.org/10.53941/ijddp.2024.100010
RIS
BibTex
Copyright & License
Copyright (c) 2024 by the authors.
This work is licensed under a This work is licensed under a Creative Commons Attribution 4.0 International License.